Baidu
map

Stem Cell Rep:自身干细胞可以治疗痴呆症

2015-01-07 佚名 生物谷

近日,来自鲁汶大学的研究人员通过研究开发出了治疗遗传性痴呆症的新型疗法,文章中研究人员将病人机体的干细胞转化成为受痴呆影响的神经元细胞,在携带易致痴呆突变的病人机体的干细胞中,研究者发现了一种可以抑制正常神经发育的靶向性缺失,而当这种缺失被修正后,这些干细胞就会回归正常状态,相关研究刊登于国际杂志Stem Cell Reports上。 研究者Catherine Verfaillie表示,利用

近日,来自鲁汶大学的研究人员通过研究开发出了治疗遗传性痴呆症的新型疗法,文章中研究人员将病人机体的干细胞转化成为受痴呆影响的神经元细胞,在携带易致痴呆突变的病人机体的干细胞中,研究者发现了一种可以抑制正常神经发育的靶向性缺失,而当这种缺失被修正后,这些干细胞就会回归正常状态,相关研究刊登于国际杂志Stem Cell Reports上。

研究者Catherine Verfaillie表示,利用诱导多能性干细胞技术,我们就可以制造出模拟痴呆症的模型来供研究,额颞障碍是由大脑中额叶和颞叶的神经元损失而引发的一种疾病,其通常会导致患者行为障碍或语言障碍及情感障碍等;而一种名为颗粒蛋白前体(GRN)的基因的突变往往和额颞痴呆(frontotemporal dementia)的发病直接相关,但小鼠机体中GRN突变并不会表现出和人类疾病完全相似的症状,从而就影响了治疗人类疾病疗法的开发。

研究者表示,如今我们就可以利用诱导多能性干细胞来理解痴呆症的发病机制,尤其是揭示额颞痴呆的发病机理,这项研究中研究人员从三名病人机体中构建了携带GRN突变的诱导多能性干细胞,这些不成熟的细胞在转化为成熟的过程中发生了损伤,而在额颞痴呆中往往是一种名为皮层神经元的细胞会受到损伤。

在研究人员构建的诱导多能性干细胞中一种缺失的通路就为Wnt信号通路,该信号路径在神经发育过程中扮演着重要角色,然而遗传修正或药物疗法就会帮助恢复诱导多能性干细胞向皮层神经元的能力,本文研究显示,GRN突变会通过改变Wnt信号通路的方式来引发皮层神经元形成的缺失。

最后研究者指出,神经发育过程中一系列的信号事件或许在神经发育中扮演重要的角色,而靶向这些信号通路,比如Wnt信号路径或许就可以帮助开发治疗额颞痴呆的新型靶向,下一步研究人员计划进行深入研究来理解GRN突变细胞为何会引发疾病,同时也可以帮助鉴别出新型的药物靶点。

原始出处

Raitano S1, Ordovàs L1, De Muynck L2, Guo W2, Espuny-Camacho I3, Geraerts M1, Khurana S1, Vanuytsel K1, Tóth BI4, Voets T4, Vandenberghe R5, Cathomen T6, Van Den Bosch L2, Vanderhaeghen P7, Van Damme P8, Verfaillie CM9.Restoration of Progranulin Expression Rescues Cortical Neuron Generation in an Induced Pluripotent Stem Cell Model of Frontotemporal Dementia.Stem Cell Reports. 2014 Dec 30.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959239, encodeId=a4ce1959239b6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Feb 01 21:09:00 CST 2015, time=2015-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836096, encodeId=34f21836096c1, content=<a href='/topic/show?id=4613e1212fc' target=_blank style='color:#2F92EE;'>#痴呆症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71212, encryptionId=4613e1212fc, topicName=痴呆症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Thu Aug 13 08:09:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868988, encodeId=217b1868988fb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jun 18 19:09:00 CST 2015, time=2015-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794377, encodeId=6a151e94377d4, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Aug 30 18:09:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481851, encodeId=882f14818510c, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Fri Jan 09 00:09:00 CST 2015, time=2015-01-09, status=1, ipAttribution=)]
    2015-02-01 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1959239, encodeId=a4ce1959239b6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Feb 01 21:09:00 CST 2015, time=2015-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836096, encodeId=34f21836096c1, content=<a href='/topic/show?id=4613e1212fc' target=_blank style='color:#2F92EE;'>#痴呆症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71212, encryptionId=4613e1212fc, topicName=痴呆症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Thu Aug 13 08:09:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868988, encodeId=217b1868988fb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jun 18 19:09:00 CST 2015, time=2015-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794377, encodeId=6a151e94377d4, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Aug 30 18:09:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481851, encodeId=882f14818510c, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Fri Jan 09 00:09:00 CST 2015, time=2015-01-09, status=1, ipAttribution=)]
    2015-08-13 Boyinsh
  3. [GetPortalCommentsPageByObjectIdResponse(id=1959239, encodeId=a4ce1959239b6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Feb 01 21:09:00 CST 2015, time=2015-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836096, encodeId=34f21836096c1, content=<a href='/topic/show?id=4613e1212fc' target=_blank style='color:#2F92EE;'>#痴呆症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71212, encryptionId=4613e1212fc, topicName=痴呆症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Thu Aug 13 08:09:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868988, encodeId=217b1868988fb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jun 18 19:09:00 CST 2015, time=2015-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794377, encodeId=6a151e94377d4, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Aug 30 18:09:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481851, encodeId=882f14818510c, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Fri Jan 09 00:09:00 CST 2015, time=2015-01-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1959239, encodeId=a4ce1959239b6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Feb 01 21:09:00 CST 2015, time=2015-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836096, encodeId=34f21836096c1, content=<a href='/topic/show?id=4613e1212fc' target=_blank style='color:#2F92EE;'>#痴呆症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71212, encryptionId=4613e1212fc, topicName=痴呆症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Thu Aug 13 08:09:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868988, encodeId=217b1868988fb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jun 18 19:09:00 CST 2015, time=2015-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794377, encodeId=6a151e94377d4, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Aug 30 18:09:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481851, encodeId=882f14818510c, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Fri Jan 09 00:09:00 CST 2015, time=2015-01-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1959239, encodeId=a4ce1959239b6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Feb 01 21:09:00 CST 2015, time=2015-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836096, encodeId=34f21836096c1, content=<a href='/topic/show?id=4613e1212fc' target=_blank style='color:#2F92EE;'>#痴呆症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71212, encryptionId=4613e1212fc, topicName=痴呆症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Thu Aug 13 08:09:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868988, encodeId=217b1868988fb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jun 18 19:09:00 CST 2015, time=2015-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794377, encodeId=6a151e94377d4, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Aug 30 18:09:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481851, encodeId=882f14818510c, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Fri Jan 09 00:09:00 CST 2015, time=2015-01-09, status=1, ipAttribution=)]

相关资讯

盘点:2014年Cell 杂志亮点研究成果

不知不觉,2014年马上就要过去了,迎接我们的将是崭新的2015年,2014年三大国际著名杂志Cell、Nature和Science(CNS)依然刊登了很多亮点耐人寻味的研究,本文中小编就盘点了2014年Cell杂志及其子刊发表的一些非常有意义的亮点研究。Cell及其子刊:[1] Cancer Cell:科学家发现新型抗癌小分子约翰霍普金斯大学科学家在培养细胞体系中发现一种小分子具有破坏癌细胞

Nat Commu:帕金森病中胶质细胞与干细胞对疾病治疗可能很重要

中科院深圳先进技术研究院王立平课题组首次发现特异性地激活胶质细胞可促进干细胞分化并修复受损帕金森氏病脑组织,有望为探讨帕金森氏病的发病机制和治疗新方法带来新的希望。相关成果12月18日发表在国际著名学术刊物《自然-通讯》。 据悉,帕金森氏病在中国60岁以上老年人群中患病率为1%-2%,且每年递增并呈年轻化趋势。传统的药物治疗方法会随着疾病的发展产生耐药性,增大药量后 会对机体产

卫计委:中国干细胞临床研究的规范性文件即将颁布!

干细胞临床应用数年前被叫停后,中国相关政策趋于谨慎。但据财新记者了解,一项新的规范性政策正在酝酿。 国家卫计委会同国家食药总局日前召开了干细胞临床研究专家委员会会议,会议形成的意见正逐级上报,等待最后的签发出台。据国家卫计委人士对财新记者透露,由此,新的干细胞项目研究和开发的监管政策已获基本共识,如果不出意外,正式文件有望近期通过,其主旨还是推动中国干细胞研究的进展。 国家卫计委人士对财新记者

Nature:新型单细胞分析技术揭示干细胞中的复杂突变

近日,来自波士顿儿童医院等处的研究人员利用新型的单细胞基因分析技术揭示了多能干细胞的多种遗传突变,相关研究刊登于国际著名杂志Nature上,为后期开发治疗疾病的新型再生性疗法提供了一定的帮助和希望。 研究者James Collins表示,在单一细胞之间干细胞群体会包含许多差异,而这在干细胞工程学领域开发预测性的方法却会带来一点问题,如今研究者发现,他们此前考虑过的细胞间的问题性差异或许实际上

利用干细胞生成多巴胺神经元治疗帕金森氏病

墨西哥科学家通过实验证实,在成年帕金森氏病大鼠中,运动性能可以恢复。 帕金森氏病是一种运动系统退行性疾病。虽然该实验结果还没有被转移到临床,但新研究提供了对抗这种疾病的研究基础。 Jorge Aceves Ruiz等科研人员利用干细胞产生多巴胺的神经细胞,激活有震颤性麻痹或帕金森氏病症状大鼠大脑生成多巴胺。Aceves Ruiz拥有超过35年的脑生理学研究经验,但特别是对于基底神经节。

Virchows Arch:CD133在区分乳管内乳头状侵袭良恶性肿瘤的诊断价值

Virchows Arch:CD133在区分乳管内乳头状侵袭良恶性肿瘤的诊断价值 研究背景:乳腺乳头状癌在新诊断乳腺癌中所占比例不到2%,常发生与绝经后妇女,因其组织学表现为手指样或乳头样凸起而得名。乳头状癌与导管原位癌有相似的预后和预测因素,因此区分导管内乳头状瘤和乳头状癌尤为重要。然而由于发病率较低、形态学多变(有些特征与非典型乳头状瘤相似)、诊断常常很困难。肿瘤干细胞这一概念的兴起为肿

Baidu
map
Baidu
map
Baidu
map